β-Arrestins (Arrb) participate in the regulation of multiple signaling pathways, including Wnt/β-catenin, the major actor in human colorectal cancer initiation. To better understand the roles of Arrb in intestinal tumorigenesis, a reverse genetic approach (Arrb −/− ) and in vivo siRNA treatment were used in Apc Δ14/+ mice. Mice with Arrb2 depletion (knockout and siRNA) developed only 33% of the tumors detected in their Arrb2-WT littermates, whereas Arrb1 depletion remained without significant effect. These remaining tumors grow normally and are essentially Arrb2-independent. Unsupervised hierarchical clustering analysis showed that they clustered with 25% of Apc
Δ14/+
;Arrb2 +/+ tumors. Genes overexpressed in this subset reflect a high interaction with the immune system, whereas those overexpressed in Arrb2-dependent tumors are predominantly involved in Wnt signaling, cell adhesion, migration, and extracellular matrix remodeling. The involvement of Arrb2 in intestinal tumor development via the regulation of the Wnt pathway is supported by ex vivo and in vitro experiments using either tumors from Apc Δ14/+ mice or murine Apc Min/+ cells. Indeed, Arrb2 siRNAs decreased the expression of Wnt target genes in cells isolated from 12 of 18 tumors from Apc Δ14/+ mice. In Apc Min/+ cells, Arrb2 siRNAs completely reversed the increased Wnt activity and colony formation in soft agar induced by Apc siRNA treatment, whereas they did not affect these parameters in basal conditions or in cells expressing constitutively active β-catenin. We demonstrate that Arrb2 is essential for the initiation and growth of intestinal tumors displaying elevated Wnt pathway activity and identify a previously unsuspected molecular heterogeneity among tumors induced by truncating Apc mutations.
tumor initiation | carcinogenesis B iallelic disruption of tumor-suppressor genes (1) and the acquisition of dominant-activating mutations of oncogenes (2) are considered as founding events of tumorigenesis. Tumor diversity, the soil of tumor evolution, is thought to emerge with time from these genetic alterations. In the case of colorectal tumorigenesis, the earliest genetic event is the activation of Wnt signaling through the genetic disruption of the tumor-suppressor gene adenomatous polyposis coli (APC) (3) . It is estimated that 80% of colorectal tumors carry somatic mutations of APC and, although its loss of function is associated with microadenoma formation (4), the mechanisms underlying macroscopic tumor development remain elusive.
Nonvisual β-arrestins, β-arrestin1 (Arrb1) and β-arrestin2 (Arrb2), are ubiquitous proteins initially described for their role in G protein-coupled receptors desensitization, sequestration, and internalization (5). More recently, many studies have uncovered unexpected functions for Arrb as scaffold proteins for many signaling molecules in the cytoplasm and nucleus, thus regulating gene expression and cellular responses (6) . As an example, Arrb modulate ERK, c-Jun NH2-terminal kinase, and phospho-inositide 3-kinase, kinases that are strongly activated in malignant cells (6) . Arrb are overexpressed in late-stage cancers, such as human glioblastomas (7) and breast cancer (8) , and have been assigned several functions in tumor cells, including proliferation (9), apoptosis (10), migration, and invasion (11) . Arrb were also reported to regulate Wnt signaling in nonintestinal models (12) . Indeed, Arrb1 interacts with phosphorylated dishevelled (Dsh) 1 and Dsh2 and enhances transcription factor-4 (Tcf-4)-mediated transcriptional activity in HEK293 cells (13) . Arrb2 interacts with Dsh2 to mediate Wnt5A-stimulated endocytosis of Frizzled 4 (14) and interacts with Axin and Dsh after Wnt3A stimulation of mouse embryo fibroblasts, resulting in inactivation of glycogen synthase kinase 3β and stabilization of β-catenin (15) . Thus, we hypothesized that Arrb could play a role in intestinal tumorigenesis initiated by the activation of Wnt signaling, and we studied the effects of Arrb gene deletion on intestinal tumorigenesis using Apc Δ14/+ mice, a relevant mouse model of human intestinal carcinogenesis (16) . Our results establish a critical role for Arrb2 at an early stage of adenoma formation and unravel a previously unsuspected diversity among Apc Δ14/+ mouse tumors.
Results
Depletion of Arrb2, but Not Arrb1, Decreases Intestinal Tumor Number in Apc Δ14/+ Mice. To unravel the role of Arrb in intestinal tumorigenesis, Apc Δ14/+ mice, which spontaneously develop intestinal tumors (16) that express heterogeneous levels of Arrb1 and Arrb2 mRNA (Fig. S1A ), were crossed with Arrb1 or Arrb2-null mice (17, 18) . Arrb1 or Arrb2 protein expression was not detected in mucosa from Apc Δ14/+ ;Arrb1 −/− (Fig. 1A) or Apc Δ14/+ ; Arrb2 −/− (Fig. 1B) , respectively. Although Arrb1 depletion had no significant effect, 3.5-mo-old Apc Δ14/+ ;Arrb2 −/− mice displayed a significantly lower number of tumors (33%) than control littermates (Fig. 1C) . This was indeed due to β-arrestin2 deletion and not to a compensatory change in Arrb1 mRNA levels, because the latter were not modified in Arrb2 −/− mice ( Fig. S1 B and C). Analysis of Arrb1 −/− and Arrb2 −/− mice revealed no alterations in the architecture or in the proliferation (Ki67 immunostaining) of the small intestine or the colon (Fig. S2) .
In additional experiments, specific siRNAs against Arrbs were administered during 4 wk to 4.5-mo-old Apc Δ14/+ to determine the impact of Arrb1 and Arrb2 deletion on the fate of preexisting tumors. The efficacy of Arrb1-and Arrb2-targeting siRNAs was validated on CMT-93 mouse colorectal cancer cells in vitro ( Fig.  S3 A and B) . Efficient in vivo delivery of Arrb2 siRNAs to intestinal crypts and tumors was verified ( Fig. S3 C and D) , and these siRNAs selectively decreased the expression level of Arrb1 (by ≈50%) and Arrb2 mRNA (by ≈60%) in healthy and tumor tissue ( Fig. 1 D and E) . Treatment of Apc Δ14/+ mice with Arrb2 siRNA significantly decreased (by 65%; SI Discussion) the number of tumors, whereas Arrb1 siRNA treatment had no significant effect (Fig. 1F ). All these data suggest that Arrb2 plays a crucial role in intestinal tumorigenesis in Apc Δ14/+ mice.
Arrb2 Is Essential for the Initiation and Growth of Some, but Not All
Intestinal Tumors in Apc-Mutated Mice. To assess the effect of Arrb2 deficiency on tumor growth, we measured the size of tumors remaining in both models of Arrb2-depleted Apc Δ14/+ mice. Surprisingly, the decreased tumor number was not accompanied by a decrease in tumor size in both Apc Δ14/+ ;Arrb2 Fig. 2A ) and Arrb2 siRNA-treated mice (Fig. 2B ). Furthermore, there was no difference in Ki67 and cyclin-D1 staining or in BrdU incorporation in residual tumors of Apc Δ14/+ ;Arrb2 −/− mice and Arrb2 siRNA-treated Apc Δ14/+ mice compared with randomly selected tumors in their respective controls (Fig. 2C) , indicating that the proliferative status does not discriminate tumors that manage to grow in Apc Δ14/+ ;Arrb2 −/− mice from overall Apc Δ14/+ tumors. Taken together, these results suggest that Arrb2 is essential for the initial development and growth of 67% of tumors in Apc Δ14/+ mice, whereas remaining tumors are essentially independent from Arrb2. Thus, because the decreased number of tumors in Apc Δ14/+ ;Arrb2 −/− mice is not accompanied by a decrease in tumor size and cannot be explained by a change in proliferation or migration rate (Fig. S4) , we analyzed whether Arrb2-dependent and -independent tumors displayed different molecular profiles.
Molecular Analysis of Arrb2-Dependent and -Independent Tumors in Apc
Δ14/+ Tumors. Although the same Apc mutation is present in every cell of Apc Δ14/+ mice, the identification of Arrb2-dependent and -independent tumors was suggestive of an early tumor heterogeneity in this mouse model. Thus, we hypothesized that molecular differences may allow us to discriminate two subset of tumors in Apc . Effect of Arrb1 and Arrb2 siRNA treatment on Arrb1 (D) and Arrb2 (E) mRNA expression in adenomas and adjacent healthy mucosa. n = 4 tumors or healthy tissues from different mice; *P < 0.05 vs. corresponding control siRNA. (F) Tukey box plots show the number of adenomas per Apc Δ14/+ mouse after treatment with siRNA targeting either the Arrb1 (n = 9) or Arrb2 mRNA (n = 9), compared with control siRNA. n = 7; *P < 0.05, Arrb2 vs. control siRNA. Arrb2 −/− mice (T2b) (Fig. 3A and Fig. S5A ). These data strongly suggest that two molecularly heterogeneous tumor subsets coexist in Apc Δ14/+ mice and that, as hypothesized, only a subset of Apc ;Arrb2 −/− tumors. Strikingly, the proportion of tumors that managed to grow in the Apc Δ14/+ ;Arrb2 −/− background (33%) is equivalent to the proportion of Apc Δ14/+ ;Arrb2 +/+ tumors that were found to cluster with them. We propose that these tumors are Arrb2-independent and grow normally in Apc Δ14/+ ;Arrb2 −/− mice, whereas T1 tumors are Arrb2-dependent and are therefore eradicated upon Arrb2 depletion. An independent prospective gene expression analysis further validated this molecular heterogeneity between 10 additional tumors of 3.5-mo-old Apc Δ14/+ mice ( Fig. S5 C and D) .
A differential expression analysis of the microarray data using linear models for microarray analysis (19) showed that 1,316 genes were differentially expressed between T1 and T2a tumors ( Fig.  S5B ; SI Discussion), with 429 genes overexpressed in the T1 (Arrb2-dependent) subset and 887 overexpressed in T2a (Arrb2-independent) tumors (Tables S1 and S2). A gene ontology (GO) analysis pointed to major differences between these two sets of genes, with genes overexpressed in T1 tumors mostly falling under the Wnt pathway, cell adhesion, cell migration, and extracellular matrix organization and remodeling GO terms, whereas genes overexpressed in T2a tumors are essentially associated with the regulation of the immune system (Fig. 3B) .
Of note, a large number of genes overexpressed in Arrb2-dependent tumors are involved in the Wnt pathway, including prospero-related homeobox 1 (Prox1), SRY-box containing gene (Sox) 4 and 9, claudin-2 (Cldn2), β-catenin (Ctnnb1), and the leucine-rich repeat containing G protein coupled receptor 5 (Lgr5), a stem cell marker (20) (Fig. 3C) . (Fig. 3C) . In contrast, Arrb2-independent tumors overexpress a number of genes involved in immune system regulation, such as those coding for mucosal addressin cell adhesion molecule 1, vascular cell adhesion molecule 1, and intercellular adhesion molecule 2, that mediate the adhesion of leukocytes to vascular endothelium (Fig. 3D) . The tumor heterogeneity described above at the gene expression level was confirmed at the protein expression level by immunofluorescence. Indeed, a large majority of tumors in Apc Δ14/+ mice expressed high levels of Prox1 and Clnd2 and low levels of Cd45, whereas the remaining tumors expressed low levels of Prox1 and Cldn2 proteins and high levels of Cd45. These data suggest that the former are the Arrb2-dependent tumors and that the latter are infiltrated by immune cells and represent the Arrb2-independent subgroup (Fig. 3E ). All these results reflect the presence of a significant molecular heterogeneity between Arrb2-dependent and -independent tumors downstream from the Apc mutation and suggest that Arrb2-dependent tumors have a higher level of Wnt target activation than their Arrb2-independent counterparts.
Ex Vivo Arrb2 Down-Regulation Differentially Decreases Wnt Target Gene Expression in Cells Isolated from Apc Δ14/+ Mouse Tumors. To further highlight the causal link between Arrb2 and the Wnt pathway in Arrb2-dependent tumors from Apc Δ14/+ mice, tumor cells were isolated from 18 adenomas stemming from three different Apc Δ14/+ mice, and the impact of Arrb2 siRNA was analyzed on the expression of three Wnt target genes (Myc, Lgr5, and Cd44). Although siRNA treatment efficiently down-regulated Arrb2 in all samples (Fig. 4A) , cells from 12 of 18 adenomas only displayed reduced expression of Myc, Lgr5, and Cd44 mRNA (Fig. 4 B-D) , whereas their expression was unaffected by Arrb2 down-regulation in 2 out of every 6 tumors per mouse. In addition, cells from the 12 responsive tumors displayed higher levels of cldn2, a representative gene of the T1 subgroup (Fig.  4E) . Moreover, Arrb2 down-regulation induced a decrease of Wnt/β-catenin activity in SW480 human colorectal cancer cells, which display elevated Wnt signaling due to a genetic inactivation of APC, but not in RKO cells, a colorectal cancer cell line displaying WT APC and normal Wnt signaling (Fig. S6) . These results confirm that Arrb2 is essential in cells with elevated Wnt activity.
Arrb2 Knockdown Prevents the Increase of β-catenin/Tcf-4 activity and Colony Formation Induced by Apc Depletion in Vitro. To ascertain whether Arrb2 could be essential for the initial step of tumor development in tumors with elevated Wnt activity, Arrb2 or control siRNA was used in murine Apc Min/+ cells in which a loss of the second Apc allele was mimicked in vitro using Apc siRNA. Efficacy of these siRNA is demonstrated in Fig. 5A . As expected, β-catenin/Tcf-4 transcriptional activity and the number of colonies increased when Apc expression was diminished (Fig. 5 B and  C) . Arrb2 depletion reversed this phenotype, whereas it was ineffective in control cells, which carry a heterozygous Apc mutation ( Fig. 5 B and C) . In the same cells, we found that the effect of Arrb2 siRNA on Apc siRNA-induced Wnt activity (Fig. 5B ) and colony formation (Fig. 5C ) was reversed by expression of a constitutively active form of β-catenin (ΔN87b-cat). In conclusion, these results strongly support the hypothesis that Arrb2 is only essential for the initiation of tumors in an elevated Wnt signaling context and is acting upstream from or on the Apc/ Gsk3β/axin complex.
Discussion
In this study, we identify the involvement of Arrb2 in intestinal tumorigenesis induced by truncating Apc mutations. We demonstrate that 67% of tumors were absent upon Arrb2 depletion in Apc-mutated mice. The remaining 33% grew normally and clustered with 25% of tumors present in Apc Δ14/+ ;Arrb2 +/+ mice in an unsupervised clustering analysis of global gene expression profiles. This observation unravels a previously unsuspected molecular heterogeneity among these tumors. One of these tumor subgroups only displays a higher level of Wnt activity, and we provide evidence in favor of a selective role for Arrb2 in this subgroup via a modulation of Wnt target gene expression.
The complete absence of 67% of tumors in both Arrb2 siRNA and Arrb2 −/− Apc-mutated mice, without any detectable effect on the size of remaining tumors, suggests that Arrb2 plays an essential role in tumor initiation. The interplay between Arrb2 and the Wnt pathway detected in our study is likely to play a role in this effect. In Apc-mutated mice, partial or complete inactivation of the second Apc allele is the earliest event of tumor initiation (4), and threshold levels of Tcf-4 activity must be attained to initiate intestinal tumors (21) . Our results indicate that the reduction of Arrb2 is only effective to decrease β-catenin/Tcf-4 activity and colony formation in soft agar when Wnt activity is experimentally increased in Apc Min/+ cells. In line with these data, we found that multiple Wnt target genes are overexpressed in the 75% of Arrb2-dependent tumors identified in Apc Δ14/+ mice, reflecting a higher β-catenin activity in these tumors compared with the Arrb2-independent subgroup. This is in line with what has been observed in patients with familial adenomatous polyposis, who also carry germinal APC mutations. In these patients, different adenomas do not seem to always undergo similar alterations of the second allele (22) . Such differences in Apc modulation likely lead to differences in β-catenin activity (23) . We therefore hypothesize that Arrb2 is essential for intestinal tumor initiation in a subset of Apc Δ14/+ adenomas displaying higher Tcf-4 activity, whereas it is dispensable for tumors originating in a lower Tcf-4 activity context. Our ex vivo and in vitro data support this hypothesis and indicate that the regulation of the Wnt pathway by Arrb2 can occur directly at the level of epithelial tumor cells. These data are also in agreement with the observation showing that the renewal of healthy intestinal crypts is similar in Apc Δ14/+
;Arrb2
−/− and in Apc Δ14/+ ;Arrb2 +/+ mice, corroborating the lack of effect of Arrb2 depletion on the growth or survival of cells with subthreshold Tcf-4 activity. Finally, this dependency clearly does not require overexpression of Arrb2, because Arrb2-dependent tumors actually express slightly lower levels of Arrb2 than the subgroup of independent tumors.
What could be the molecular mechanism involved in the regulation by Arrb2 of Apc mutation-induced tumorigenesis? Because the inhibitory effects of Arrb2 depletion is only detected in models in which the β-catenin degradation complex (Apc/ Gsk3β/Axin) is at best poorly effective (Apc Δ14/+ mice or Apc
Min/+ cells treated with Apc siRNA), and because the expression of a constitutively activated β-catenin mutant reversed Arrb2 siRNA inhibition on Wnt activity and colony formation induced by Apc depletion in Apc Min/+ cells, it is tempting to speculate that Arrb2 regulates Wnt signaling upstream from that complex. Several proteins known to interact with Arrb2 and involved in the Wnt signaling pathway could thus be potential candidates, such as Dvl2 (14) and Src (11) . Depletion of Dvl2 decreases tumor number in Apc Min/+ mice (24), which is in favor of the fact that Dvl2 can affect β-catenin/Tcf-4 activity even in a context whereby the β-catenin degradation complex is lost. Furthermore, the interaction of Dvl2 with Src has been shown to be required for the tyrosine phosphorylation of β-catenin that promotes β-catenin/Tcf-4 activity involved in ovarian cancer cell invasion and metastasis (11) . Thus, in our model, Dvl2 and Src might be potential partners by which Arrb2 regulates Apc mutationinduced tumorigenesis.
Unexpectedly, the identification of two subsets of Apc Δ14/+ tumors with very different sensitivity toward Arrb2 also helped us unravel a previously unsuspected early heterogeneity among these tumors at the gene expression level. The gene set enriched in Arrb2-dependent Apc Δ14/+ mouse tumors includes numerous genes that promote the evolution toward malignant and invasive tumors. Indeed, in vitro and in vivo studies have linked the expression of Itga6, Foxc1, and Mmp7, -10, and -12 to increased tumor cell invasion, migration, and metastasis (25) (26) (27) . Target genes of the Wnt signaling pathway such as Prox1, Sox4, Sox9, Lgr5, and Cldn2 are also involved in tumorigenesis and cancer progression (20, (28) (29) (30) (31) . By contrast, genes highly represented in Arrb2-independent tumors encode molecules mainly involved in T-and B-cell differentiation and activation, such as Cd40, Cd74, Cd86, and Il21r. In agreement with the present work, a gene profile related to the immune system correlated to underexpressed genes involved in tumor invasion and metastasis in carcinogen-induced intestinal tumors from Bcl9/Bcl9l −/− mice (32). Our results and those of that study thus provide strong arguments to suggest that a dynamic interaction between cancer cells and cells from the immune system may control tumor progression toward malignancy.
In conclusion, our data provide evidence that Arrb2 is essential for the initiation and growth of intestinal tumors displaying elevated Wnt pathway activity and identify a previously unsuspected molecular heterogeneity among tumors induced by truncating Apc mutations. This molecular diversity could have a clinical impact because it may allow the early detection of adenomas with a potential for progression toward the invasive colorectal carcinoma stage. Min/+ colony formation in soft agar after depletion of Apc or Arrb2 or both compared with control siRNA modulated or not by transfecting cells with a mutated β-catenin ΔN87β-cat. Number of colonies obtained from 30 random fields per condition (n = 4; *P < 0.001 compared with control cells and **P < 0.001 compared with Apc siRNA).
Materials and Methods
Detailed protocols are given in SI Materials and Methods. Adenoma Scoring and Immunohistochemistry. Mice received an i.p. injection of 2 mg BrdU (Sigma-Aldrich) 2 h or 48 h before being killed. Postmortem, the whole intestinal tract was removed and reversed on a skewer to count the polyps. When possible, 1 to 2 tumors (≈2-3mm) were removed from the jejunum and kept in RNAlater at −80°C for further RNA extraction. Tissue fixation and immunohistochemistry on thin sections of paraffin-embedded tissue were performed essentially as described previously (35) .
Gene Expression Profiling by Oligonucleotide Microarray. Methods for RNA labeling, microarray processing, and analysis of microarray data are available in SI Materials and Methods. Microarray data are accessible at the Gene Expression Omnibus database under accession number GSE24577.
Statistical Analysis. All data were represented as mean ± SEM, except for the Tukey boxplots that express the first and the third quartiles by the upper and lower horizontal lines in a rectangular box, inside which the horizontal line represents the median. When distribution was normal (assessed with a Skewness and Kurtosis test), an unpaired t test was used for two-group comparisons, and a one-way ANOVA followed by a Bonferroni post hoc test was used for comparisons of three or more groups. In other cases, a MannWhitney test was used for two-group comparison and a Kruskal-Wallis test followed by Dunn's post hoc test was used for three-group comparisons. For all tests, a P value of <0.05 was considered statistically significant.
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